Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)

[1]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[2]  Don M. Gash,et al.  Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys , 1995, Neurobiology of Aging.

[3]  J. Schneider,et al.  Repeated exposure to MPTP does not produce a permanent movement disorder in cats recovered from MPTP-induced parkinsonism. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[4]  J. Langston,et al.  Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions , 1994, Annals of neurology.

[5]  D. Riche,et al.  Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons , 1993, Neuroscience.

[6]  Z. Zhang,et al.  Developing a stable bilateral model of parkinsonism in rhesus monkeys , 1993, Neuroscience.

[7]  S B Dunnett,et al.  Behavioural analysis of unilateral monoamine depletion in the marmoset. , 1992, Brain : a journal of neurology.

[8]  R. Mailman,et al.  D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. , 1991, The Journal of pharmacology and experimental therapeutics.

[9]  J. Schneider.  Responses of striatal neurons to peripheral sensory stimulation in symptomatic MPTP-exposed cats , 1991, Brain Research.

[10]  B. Everitt,et al.  Scales for rating motor impairment in Parkinson's disease: studies of reliability and convergent validity. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[11]  R. Roth,et al.  Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier. , 1990, Behavioral neuroscience.

[12]  R. Roth,et al.  MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate , 1990, Neuroscience Letters.

[13]  J. Schneider,et al.  Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys , 1990, Brain Research.

[14]  R. Roth,et al.  Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys. , 1990, Brain : a journal of neurology.

[15]  H. Fibiger,et al.  Intracarotid 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Administration: Biochemical and Behavioral Observations in a Primate Model of Hemiparkinsonism , 1990, Journal of neurochemistry.

[16]  D. Jacobowitz,et al.  The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. , 1990, Journal of neurosurgery.

[17]  R. Roth,et al.  Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions , 1989, Neuroscience.

[18]  C. Marsden,et al.  Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. , 1989, Biochemical pharmacology.

[19]  C. Marsden,et al.  Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP , 1989, Neuroscience Letters.

[20]  C. Markham,et al.  Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1988, Brain : a journal of neurology.

[21]  R. Roth,et al.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF , 1987, Brain Research.

[22]  R. Bakay,et al.  Biochemical and Behavioral Correction of MPTP Parkinson‐like Syndrome by Fetal Cell Transplantation a , 1987, Annals of the New York Academy of Sciences.

[23]  C. Markham,et al.  Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP , 1987, Brain Research.

[24]  R. Roth,et al.  Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. , 1987, Life sciences.

[25]  B. Bioulac,et al.  Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data. , 1986, Electromyography and clinical neurophysiology.

[26]  T. Paolo,et al.  Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys , 1986, Brain Research.

[27]  B. A. Brooks,et al.  Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys , 1986, Neuroscience.

[28]  D. Jacobowitz,et al.  Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.

[29]  C. Marsden,et al.  Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset. , 1986, European journal of pharmacology.

[30]  C. Markham,et al.  Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior, histology, and biochemistry , 1986, Experimental Neurology.

[31]  Y. Stern,et al.  Intellectual changes in patients with MPTP‐induced parkinsonism , 1985, Neurology.

[32]  W. Schultz,et al.  Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism , 1985, Neuroscience Letters.

[33]  H. Pakkenberg,et al.  The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, The New England journal of medicine.

[34]  B. Bioulac,et al.  MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study , 1985, Brain Research.

[35]  D. Jacobowitz,et al.  Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. , 1985, Life sciences.

[36]  C. Kennard,et al.  The reliability of clinical assessment of Parkinson's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[37]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[38]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[40]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[41]  Seymour Geisser,et al.  Statistical Principles in Experimental Design , 1963 .

[42]  P. W. Bowman,et al.  PHS Public Health Service , 1963 .

[43]  R. Roth,et al.  Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. , 1995, Cell transplantation.

[44]  R. Roth,et al.  Behavioral Effects of MPTP Administration in the Vervet Monkey , 1994 .

[45]  Giuliano Geminiani,et al.  Interobserver reliability between neurologists in training of Parkinson's disease rating scales. A multicenter study , 1991, Movement disorders : official journal of the Movement Disorder Society.

[46]  R. Roth,et al.  Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys. , 1990, Progress in Brain Research.

[47]  M. Zigmond,et al.  Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. , 1989, International review of neurobiology.

[48]  S. Hunt,et al.  Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1988, Progress in brain research.

[49]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .

[50]  A J Cross,et al.  N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism. , 1986, Journal of neural transmission. Supplementum.

[51]  C. Marsden,et al.  The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. , 1986, Journal of neural transmission. Supplementum.

[52]  D. Jacobowitz,et al.  Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. , 1984, Psychopharmacology bulletin.